Technical Analysis for ITCI - Intra-Cellular Therapies Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Oversold Stochastic | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.91% | |
Narrow Range Bar | Range Contraction | 0.91% | |
Inside Day | Range Contraction | 0.91% | |
Oversold Stochastic | Weakness | 0.91% | |
Hammer Candlestick | Bullish | 1.24% | |
Oversold Stochastic | Weakness | 1.24% | |
Bullish Engulfing | Bullish | 0.25% | |
Stochastic Reached Oversold | Weakness | 0.25% | |
Outside Day | Range Expansion | 0.25% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 15 hours ago |
Rose Above 10 DMA | about 15 hours ago |
Rose Above Previous Day's High | about 17 hours ago |
10 DMA Resistance | about 17 hours ago |
Up 1% | about 17 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Intra-Cellular Therapies Inc. Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical IBD 50 Neuroscience Alzheimer's Disease Disorders Parkinson's Disease Drug Development Mental Health Schizophrenia Dysfunction Dementia Major Depressive Disorder Psychiatric Diagnosis Psychiatry Human Diseases Depressive Disorder Neurodegeneration Treatment Of Parkinson's Disease Aging Associated Diseases Autism Spectrum Disorder Bipolar Disorder Hyperactivity Disorder Insomnia Cognitive Disorders Psychiatric Disorders Cognitive Impairment Autism Learning Disabilities Phosphodiesterase Cardiovascular And Other Diseases Cognitive Dysfunction Ptsd Treatment Of Human Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 76.11 |
52 Week Low | 44.9 |
Average Volume | 800,776 |
200-Day Moving Average | 61.42 |
50-Day Moving Average | 68.79 |
20-Day Moving Average | 68.47 |
10-Day Moving Average | 65.66 |
Average True Range | 2.39 |
RSI (14) | 42.20 |
ADX | 28.76 |
+DI | 18.02 |
-DI | 30.49 |
Chandelier Exit (Long, 3 ATRs) | 68.94 |
Chandelier Exit (Short, 3 ATRs) | 69.95 |
Upper Bollinger Bands | 74.83 |
Lower Bollinger Band | 62.12 |
Percent B (%b) | 0.26 |
BandWidth | 18.56 |
MACD Line | -1.41 |
MACD Signal Line | -0.91 |
MACD Histogram | -0.4997 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 67.22 | ||||
Resistance 3 (R3) | 67.21 | 66.60 | 66.91 | ||
Resistance 2 (R2) | 66.60 | 66.13 | 66.60 | 66.80 | |
Resistance 1 (R1) | 65.98 | 65.84 | 66.29 | 65.99 | 66.70 |
Pivot Point | 65.37 | 65.37 | 65.52 | 65.37 | 65.37 |
Support 1 (S1) | 64.75 | 64.90 | 65.06 | 64.76 | 64.04 |
Support 2 (S2) | 64.14 | 64.61 | 64.14 | 63.94 | |
Support 3 (S3) | 63.52 | 64.14 | 63.83 | ||
Support 4 (S4) | 63.53 |